Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology...
Brief Summary
Official Title: “Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.”
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
- Study Type: Observational
- Study Design: Observational Model: Case Control, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective
Intervention(s) in this Clinical Trial
- Drug: piperacillin-tazobactam
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Eligible patients of either sex, 15 years of age or older
- Patients who are admitted to the department of hematology and oncology
- Provide written informed consent
Exclusion Criteria:
- Patients who have hypersensitivity to β-lactam antibiotics
- Female who are pregnant or breast-feeding
- Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 15 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Wyeth is now a wholly owned subsidiary of Pfizer Industry
Overall Clinical Trial Officials and Contacts
Medical Monitor Study Director Wyeth is now a wholly owned subsidiary of Pfizer
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00167999
Study ID Number: 0910X-101676
ClinicalTrials.gov Identifier: NCT00167999
Health Authority: Korea: Food and Drug Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00167999
